SLN Silence Therapeutics plc
Healthcare$6.64+7.10%ClosedMarket Cap: $313.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
5.93
P/S
349.34
EV/EBITDA
-4.07
DCF Value
$0.60
FCF Yield
-22.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
66.9%
Operating Margin
-9267.5%
Net Margin
-8948.4%
ROE
-107.2%
ROA
-65.2%
ROIC
-74.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $421.3K | 72.3% | $-15.0M | $-14.9M | $— | — |
| Q4 null | $34.0K | 64.7% | $-12.5M | $-11.8M | $— | — |
| FY null | $559.0K | 61.5% | $-89.8M | $-88.6M | $— | — |
| Q3 null | $159.0K | 59.7% | $-26.2M | $-21.0M | $— | — |
| Q2 null | $224.0K | 62.1% | $-24.0M | $-27.4M | $— | — |
| Q1 null | $142.0K | 62.0% | $-28.4M | $-28.5M | $— | — |
| Q4 null | $24.3M | 93.4% | $-3.1M | $14.2M | $— | — |
| FY null | $43.3M | 72.7% | $-63.3M | $-45.3M | $— | — |
| Q3 null | $1.1M | -142.9% | $-22.5M | $-27.0M | $— | — |
| Q2 null | $598.0K | -341.1% | $-18.3M | $-15.6M | $— | — |
| Q1 null | $15.7M | 82.2% | $-5.6M | $-2.3M | $— | — |
| Q4 2023 | $2.1M | 35.9% | $-13.3M | $-14.4M | $-1.08 | — |